These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11384239)

  • 1. Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists.
    Sulyok GA; Gibson C; Goodman SL; Hölzemann G; Wiesner M; Kessler H
    J Med Chem; 2001 Jun; 44(12):1938-50. PubMed ID: 11384239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of integrin antagonists containing trans- and cis-2,5-disubstituted THF rings.
    Osterkamp F; Ziemer B; Koert U; Wiesner M; Raddatz P; Goodman SL
    Chemistry; 2000 Feb; 6(4):666-83. PubMed ID: 10807178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.
    Goodman SL; Hölzemann G; Sulyok GA; Kessler H
    J Med Chem; 2002 Feb; 45(5):1045-51. PubMed ID: 11855984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
    Mousa SA; Bozarth JM; Naik UP; Slee A
    Br J Pharmacol; 2001 Jun; 133(3):331-6. PubMed ID: 11375248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential antagonism of the interactions of the integrin alpha IIb beta 3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins. Evidence supporting a functional role for the amino acid residues flanking the tripeptide RGD in determining the inhibitory properties of snake-venom RGD proteins.
    Lu X; Williams JA; Deadman JJ; Salmon GP; Kakkar VV; Wilkinson JM; Baruch D; Authi KS; Rahman S
    Biochem J; 1994 Dec; 304 ( Pt 3)(Pt 3):929-36. PubMed ID: 7529494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay.
    Wong A; Hwang SM; McDevitt P; McNulty D; Stadel JM; Johanson K
    Mol Pharmacol; 1996 Sep; 50(3):529-37. PubMed ID: 8794891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic RGD peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands.
    Marchini M; Mingozzi M; Colombo R; Guzzetti I; Belvisi L; Vasile F; Potenza D; Piarulli U; Arosio D; Gennari C
    Chemistry; 2012 May; 18(20):6195-207. PubMed ID: 22517378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiophene-based vitronectin receptor antagonists.
    Bubenik M; Meerovitch K; Bergeron F; Attardo G; Chan L
    Bioorg Med Chem Lett; 2003 Feb; 13(3):503-6. PubMed ID: 12565960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides.
    Belvisi L; Bernardi A; Checchia A; Manzoni L; Potenza D; Scolastico C; Castorina M; Cupelli A; Giannini G; Carminati P; Pisano C
    Org Lett; 2001 Apr; 3(7):1001-4. PubMed ID: 11277780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial chemistry techniques applied to nonpeptide integrin antagonists.
    Hoekstra WJ; Poulter BL
    Curr Med Chem; 1998 Jun; 5(3):195-204. PubMed ID: 9562602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid synthesis of RGD mimetics with isoxazoline scaffolds on solid phase: identification of alphavbeta3 antagonists lead compounds.
    Rockwell AL; Rafalski M; Pitts WJ; Batt DG; Petraitis JJ; DeGrado WF; Mousa S; Jadhav PK
    Bioorg Med Chem Lett; 1999 Apr; 9(7):937-42. PubMed ID: 10230615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [alphaIIbbeta3 modeling simulation and design of the cyclic RGD].
    Luo M; Chen M; Lee I
    Sheng Wu Gong Cheng Xue Bao; 2008 Feb; 24(2):297-301. PubMed ID: 18464616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements.
    Peyman A; Wehner V; Knolle J; Stilz HU; Breipohl G; Scheunemann KH; Carniato D; Ruxer JM; Gourvest JF; Gadek TR; Bodary S
    Bioorg Med Chem Lett; 2000 Jan; 10(2):179-82. PubMed ID: 10673106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.
    Meissner RS; Perkins JJ; Duong LT; Hartman GD; Hoffman WF; Huff JR; Ihle NC; Leu CT; Nagy RM; Naylor-Olsen A; Rodan GA; Rodan SB; Whitman DB; Wesolowski GA; Duggan ME
    Bioorg Med Chem Lett; 2002 Jan; 12(1):25-9. PubMed ID: 11738566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand.
    Hall ER; Bibby LI; Slack RJ
    Biochem Pharmacol; 2016 Oct; 117():88-96. PubMed ID: 27501918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative specificity of platelet alpha(IIb)beta(3) integrin antagonists.
    Thibault G; Tardif P; Lapalme G
    J Pharmacol Exp Ther; 2001 Mar; 296(3):690-6. PubMed ID: 11181894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.
    Perron-Sierra F; Saint Dizier D; Bertrand M; Genton A; Tucker GC; Casara P
    Bioorg Med Chem Lett; 2002 Nov; 12(22):3291-6. PubMed ID: 12392735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.
    Casiraghi G; Rassu G; Auzzas L; Burreddu P; Gaetani E; Battistini L; Zanardi F; Curti C; Nicastro G; Belvisi L; Motto I; Castorina M; Giannini G; Pisano C
    J Med Chem; 2005 Dec; 48(24):7675-87. PubMed ID: 16302808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
    Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
    Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships of beta-amino acid-containing integrin antagonists.
    Scarborough RM
    Curr Med Chem; 1999 Oct; 6(10):971-81. PubMed ID: 10519908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.